Abstracts Archive - Page 709 of 2607 - ACR Meeting Abstracts

Abstract Number: PP05 • ACR Convergence 2021
Fighting Health-Related Misinformation Using Social Media / How Creating an Online Group for Patients with Relapsing Polychondritis — and Moderating It with Health Professionals — Helps Spread Reliable and Empowering Information
Michael Linn¹, Spenser Mestel² and Susie Ratledge³, ¹Relapsing Polychondritis Foundation, New York, NY, ²New York, NY, ³Relapsing Polychondritis: Secular Science and Support group, Chattanooga, TN
Background/Purpose: Before I became ill in 2017, I was a registered nurse with a degree in health science who'd often educate patients about how they…
Abstract Number: PP03 • ACR Convergence 2021
Navigating Maintenance of a Rare Autoimmune Rheumatic Disease in the Context of the COVID-19 Pandemic
Ida Hakkarinen, Greenbelt, MD
Background/Purpose: On March 13th, 2020, the President of the United States issued a proclamation declaring that the outbreak of coronavirus disease 2019 (COVID-19) was a…
Abstract Number: PP02 • ACR Convergence 2021
Leveraging Digital Health Tracking to Improve Arthritis Management
Katie Roberts, Annapolis, MD
Background/Purpose: I was diagnosed with psoriasis when I was age 10 in 1986. At that time, my treatment plan consisted of regular application of Eucerin…
Abstract Number: PP10 • ACR Convergence 2021
Discovering ‘I’ Through Interaction with Support Group Members: A Place of Empathy That Transcends the Limitations of Words
Noriko Okochi¹, Eiji Oishi² and Mika Ishiguro¹, ¹Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, ²Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan
Background/Purpose: Since 5-year-old, I have had unexplained symptoms. At the age of 13, my whole body became inflamed. The pain was so intense that I…
Abstract Number: PP09 • ACR Convergence 2021
Family Planning while Living with Rheumatoid Arthritis
Shannan O'Hara-Levi, Monroe, NY
Background/Purpose: Over the course of my 30+ years living with Polyarticular Juvenile Rheumatoid Arthritis, I have never had long term success on any one biologic treatment,…
Abstract Number: PP07 • ACR Convergence 2021
How Online Spanish-Language Resources Got Me and My RA Through the COVID-19 Pandemic
Wigna Cruz, Puerto Rico
Background/Purpose: I was experiencing joint pain especially in my wrists, which led me to see my physician for testing. Initially I was misdiagnosed with lupus.…
Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Guadalupe Torres¹, Courtney Wells² and Kristine Carandang³, ¹, ²University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, ³Global Healthy Living Foundation, CreakyJoints, San Diego, CA
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
Abstract Number: PP13 • ACR Convergence 2021
CreakyKitchen: How the Online Cooking Show I Started is Building Community and Encouraging Better Food Choices for Me and Others Living with Rheumatic and Chronic Disease
Chantelle Marcial, Boston, MA
Background/Purpose: At 19, I was mis-diagnosed with Lupus as it was a common condition in my family. My treatment at that time was mainly DMARDs,…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: PP08 • ACR Convergence 2021
Should I Get the COVID-19 Vaccine With My RA? Using Evidence-Based Resources for Decision-Making
Aberdeen Allen, Colgate Palmolive, Parlin, NJ
Background/Purpose: Patients with autoimmune rheumatic diseases have concerns about getting the COVID-19 vaccine. As vaccines began to receive emergency use authorization, individuals with conditions like…
Abstract Number: PP01 • ACR Convergence 2021
Unicycling for a Cure: My UNIque Physical Activity Intervention for Rheumatoid Arthritis During the COVID19 Pandemic
Dana Guglielmo, San Diego, CA
Background/Purpose: I was diagnosed with rheumatoid arthritis at age 17. In my 20s, I joined Racing For A Cure of the Arthritis National Research Foundation,…
Abstract Number: 1946 • ACR Convergence 2021
Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients with Immune-mediated Inflammatory Diseases: A Randomized Controlled Trial
Silje Watterdal Syversen¹, Guro Goll¹, Kristin Jørgensen², Marthe Brun¹, Øystein Sandanger³, Kristin Hammersbøen², Joseph Sexton¹, Inge Olsen³, Johanna Gehin⁴, David Warren³, Rolf Anton Klaasen³, Trude Bruun⁵, Maud Kristine Ljoså⁶, Anne Haugen⁷, Rune Njålla⁸, Brigitte Michelsen⁹, Camilla Zettel¹⁰, Yngvill Bragenes¹¹, Svanaug Skorpe¹², Eldri Strand¹³, Pawel Mielnik¹⁴, Cato Mørk¹⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad¹⁶ and Espen Haavardsholm¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Lillehammer, Nepal, ⁵The University Hospital of North Norway, Tromsø, Norway, ⁶Dept. of Rheumatology, Ålesund Hospital, Ålesund, Norway, ⁷Østfold Hospital Trust, Moss, Norway, ⁸Nordland Hospital Trust, Bodø, Bodø, Norway, ⁹Hospital of Southern Norway Trust, Kristiansand, Norway, ¹⁰Betanien Hospital, Skien, Norway, ¹¹Vestre Viken Hospital Trust, Drammen, Norway, ¹²Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ¹³Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ¹⁴Førde Hospital Trust, Førde, Norway, ¹⁵Akershus Dermatology Center, Lørenskog, Norway, ¹⁶Oslo University Hospital, Radiumhospitalet, Oslo, Norway
Background/Purpose: Proactive therapeutic drug monitoring (TDM), a treatment strategy based on scheduled assessments of serum drug levels, has been proposed to optimize efficacy and safety…
Abstract Number: 1916 • ACR Convergence 2021
Antibodies to Malondialdehyde-Acetaldehyde (MAA) Modified Proteins Predict Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease
Bryant England¹, Geoffrey Thiele¹, Dana Ascherman², Michael Duryee¹, Carlos Hunter¹, Yangyuna Yang¹, Punyasha Roul¹, Harlan Sayles¹, Andreas Reimold³, Gail Kerr⁴, Joshua Baker⁵, Jill Poole¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA, ³University of Texas – Southwestern Medical Center/Dallas Veterans Affairs Medical Center (VAMC), Dallas, TX, ⁴Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Because interstitial lung disease (ILD) causes substantial morbidity and mortality in rheumatoid arthritis (RA), there is a need for methods to facilitate early identification…
Abstract Number: 1884 • ACR Convergence 2021
Real-life Data for the Use of Anti-TNF Treatment in DADA2
Omer Karadag¹, Gizem Ayan², Ozge Basaran³, Ertugrul Cagri bolek⁴, Levent Kilic², Yelda Bilginer⁵, Mehmet Alikasifoglu⁶ and Seza Ozen⁷, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University Pediatric Rheumatology, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁶Hacettepe University, Department of Medical Genetics, Ankara, Turkey, ⁷Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 enzyme (DADA2) is an autosomal recessive autoinflammatory disorder associated with ADA2 mutations. ADA2 works as a growth factor and…
Abstract Number: 1886 • ACR Convergence 2021
Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis
K. Bates Gribbons¹, SEMA KAYMAZ-TAHRA², Fatma Alibaz³, Ertugrul Cagri bolek⁴, Omer Karadag⁵, Burak Ince⁶, Murat Inanc⁷, Sinem Kocaer⁸, Fatos Onen⁹, KENAN AKSU¹⁰, Gokhan Keser¹¹, Askin Ates¹², Ayten Yazici¹³, Ayse Cefle¹³, Nilufer Alpay Kanitez¹⁴, Ahmet Omma¹⁵, Onay Gercik¹⁶, Servet Akar¹⁷, Veli Cobankara¹⁸, Nazife Sule Yasar Bilge¹⁹, Timucin Kasifoglu²⁰, Mete Kara¹¹, Kaitlin Quinn²¹, Peter Grayson²², Peter Merkel²³ and Haner Direskeneli²⁴, ¹McGovern Medical School, Colleyville, TX, ²Marmara University Faculty of Medicine, Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul University Faculty of Medicine, Istanbul, Turkey, ⁸Dokuz Eylul University, Izmer, Turkey, ⁹Dokuz Eylul University, Izmir, Turkey, ¹⁰EGE UNIV. FACULTY of MEDICINE, IZMIR, Turkey, ¹¹Ege University, İzmir, Turkey, ¹²Ankara University, Ankara, Turkey, ¹³Kocaeli University, Kocaeli, Turkey, ¹⁴Koc University School of Medicine, Istanbul, Turkey, ¹⁵Ankara City Hospital, Istanbul, Turkey, ¹⁶Izmir Katip Celebi University, Izmir, Turkey, ¹⁷Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁸Pamukkale University, Denizli, Turkey, ¹⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ²⁰Osmangazi University Department of Rheumatology, Eskişehir, Turkey, ²¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²³University of Pennsylvania, Philadelphia, PA, ²⁴Marmara University, Istanbul, Turkey
Background/Purpose: Previous studies using computer-driven methods have identified subsets of patients with Takayasu’s arteritis based on angiographic patterns of disease. These subsets were consistent between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].